|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 29306 |
FusionGeneSummary for PTGDS_CLU |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: PTGDS_CLU | Fusion gene ID: 29306 | Hgene | Tgene | Gene symbol | PTGDS | CLU | Gene ID | 5730 | 1191 |
| Gene name | prostaglandin D2 synthase | clusterin | |
| Synonyms | L-PGDS|LPGDS|PDS|PGD2|PGDS|PGDS2 | AAG4|APO-J|APOJ|CLI|CLU1|CLU2|KUB1|NA1/NA2|SGP-2|SGP2|SP-40|TRPM-2|TRPM2 | |
| Cytomap | 9q34.3 | 8p21.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | prostaglandin-H2 D-isomerasePGD2 synthasebeta-trace proteincerebrin-28glutathione-independent PGD synthaseglutathione-independent PGD synthetaselipocalin-type prostaglandin D synthaseprostaglandin D synthaseprostaglandin D2 synthase 21kDa (brain) | clusterinaging-associated protein 4apolipoprotein Jcomplement cytolysis inhibitorcomplement lysis inhibitorcomplement-associated protein SP-40,40ku70-binding protein 1sulfated glycoprotein 2testosterone-repressed prostate message 2 | |
| Modification date | 20180519 | 20180527 | |
| UniProtAcc | P41222 | P10909 | |
| Ensembl transtripts involved in fusion gene | ENST00000224167, ENST00000371625, ENST00000460340, | ENST00000316403, ENST00000546343, ENST00000560366, ENST00000405140, ENST00000523500, | |
| Fusion gene scores | * DoF score | 11 X 8 X 3=264 | 14 X 17 X 5=1190 |
| # samples | 13 | 18 | |
| ** MAII score | log2(13/264*10)=-1.02202630633 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(18/1190*10)=-2.72489276186563 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: PTGDS [Title/Abstract] AND CLU [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | Tumor suppressor gene involved fusion gene, in-frame but not retained their domain. Tumor suppressor gene involved fusion gene, retained protein feature but frameshift. DDR (DNA damage repair) gene involved fusion gene, in-frame but not retained their domain. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | PTGDS | GO:0001516 | prostaglandin biosynthetic process | 20667974 |
| Tgene | CLU | GO:0000902 | cell morphogenesis | 15857407 |
| Tgene | CLU | GO:0001774 | microglial cell activation | 15857407 |
| Tgene | CLU | GO:0017038 | protein import | 24446231 |
| Tgene | CLU | GO:0032463 | negative regulation of protein homooligomerization | 22179788|23106396 |
| Tgene | CLU | GO:0032464 | positive regulation of protein homooligomerization | 22179788 |
| Tgene | CLU | GO:0032760 | positive regulation of tumor necrosis factor production | 15857407 |
| Tgene | CLU | GO:0045429 | positive regulation of nitric oxide biosynthetic process | 15857407 |
| Tgene | CLU | GO:0050821 | protein stabilization | 11123922 |
| Tgene | CLU | GO:0051131 | chaperone-mediated protein complex assembly | 17412999 |
| Tgene | CLU | GO:0051788 | response to misfolded protein | 19996109 |
| Tgene | CLU | GO:0061077 | chaperone-mediated protein folding | 11123922 |
| Tgene | CLU | GO:0061518 | microglial cell proliferation | 15857407 |
| Tgene | CLU | GO:1900221 | regulation of amyloid-beta clearance | 24446231 |
| Tgene | CLU | GO:1901214 | regulation of neuron death | 17412999 |
| Tgene | CLU | GO:1901216 | positive regulation of neuron death | 15857407 |
| Tgene | CLU | GO:1902430 | negative regulation of amyloid-beta formation | 12047389|17412999 |
| Tgene | CLU | GO:1905907 | negative regulation of amyloid fibril formation | 22179788 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | LD | LGG | TCGA-CS-4944-01A | PTGDS | chr9 | 139872144 | + | CLU | chr8 | 27455767 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| In-frame | ENST00000224167 | ENST00000316403 | PTGDS | chr9 | 139872144 | + | CLU | chr8 | 27455767 | - |
| Frame-shift | ENST00000224167 | ENST00000546343 | PTGDS | chr9 | 139872144 | + | CLU | chr8 | 27455767 | - |
| Frame-shift | ENST00000224167 | ENST00000560366 | PTGDS | chr9 | 139872144 | + | CLU | chr8 | 27455767 | - |
| In-frame | ENST00000224167 | ENST00000405140 | PTGDS | chr9 | 139872144 | + | CLU | chr8 | 27455767 | - |
| Frame-shift | ENST00000224167 | ENST00000523500 | PTGDS | chr9 | 139872144 | + | CLU | chr8 | 27455767 | - |
| In-frame | ENST00000371625 | ENST00000316403 | PTGDS | chr9 | 139872144 | + | CLU | chr8 | 27455767 | - |
| Frame-shift | ENST00000371625 | ENST00000546343 | PTGDS | chr9 | 139872144 | + | CLU | chr8 | 27455767 | - |
| Frame-shift | ENST00000371625 | ENST00000560366 | PTGDS | chr9 | 139872144 | + | CLU | chr8 | 27455767 | - |
| In-frame | ENST00000371625 | ENST00000405140 | PTGDS | chr9 | 139872144 | + | CLU | chr8 | 27455767 | - |
| Frame-shift | ENST00000371625 | ENST00000523500 | PTGDS | chr9 | 139872144 | + | CLU | chr8 | 27455767 | - |
| intron-3CDS | ENST00000460340 | ENST00000316403 | PTGDS | chr9 | 139872144 | + | CLU | chr8 | 27455767 | - |
| intron-3CDS | ENST00000460340 | ENST00000546343 | PTGDS | chr9 | 139872144 | + | CLU | chr8 | 27455767 | - |
| intron-3CDS | ENST00000460340 | ENST00000560366 | PTGDS | chr9 | 139872144 | + | CLU | chr8 | 27455767 | - |
| intron-3CDS | ENST00000460340 | ENST00000405140 | PTGDS | chr9 | 139872144 | + | CLU | chr8 | 27455767 | - |
| intron-3CDS | ENST00000460340 | ENST00000523500 | PTGDS | chr9 | 139872144 | + | CLU | chr8 | 27455767 | - |
Top |
FusionProtFeatures for PTGDS_CLU |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| PTGDS | CLU |
| Catalyzes the conversion of PGH2 to PGD2, aprostaglandin involved in smooth muscle contraction/relaxation anda potent inhibitor of platelet aggregation. Involved in a varietyof CNS functions, such as sedation, NREM sleep and PGE2-inducedallodynia, and may have an anti-apoptotic role inoligodendrocytes. Binds small non-substrate lipophilic molecules,including biliverdin, bilirubin, retinal, retinoic acid andthyroid hormone, and may act as a scavenger for harmfulhydrophopic molecules and as a secretory retinoid and thyroidhormone transporter. Possibly involved in development andmaintenance of the blood-brain, blood-retina, blood-aqueous humorand blood-testis barrier. It is likely to play important roles inboth maturation and maintenance of the central nervous system andmale reproductive system. {ECO:0000269|PubMed:20667974,ECO:0000269|PubMed:9475419}. | Isoform 1 functions as extracellular chaperone thatprevents aggregation of nonnative proteins. Prevents stress-induced aggregation of blood plasma proteins. Inhibits formationof amyloid fibrils by APP, APOC2, B2M, CALCA, CSN3, SNCA andaggregation-prone LYZ variants (in vitro). Does not require ATP.Maintains partially unfolded proteins in a state appropriate forsubsequent refolding by other chaperones, such as HSPA8/HSC70.Does not refold proteins by itself. Binding to cell surfacereceptors triggers internalization of the chaperone-client complexand subsequent lysosomal or proteasomal degradation. Secretedisoform 1 protects cells against apoptosis and against cytolysisby complement. Intracellular isoforms interact with ubiquitin andSCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligasecomplexes and promote the ubiquitination and subsequentproteasomal degradation of target proteins. Promotes proteasomaldegradation of COMMD1 and IKBKB. Modulates NF-kappa-Btranscriptional activity. Nuclear isoforms promote apoptosis.Mitochondrial isoforms suppress BAX-dependent release ofcytochrome c into the cytoplasm and inhibit apoptosis. Plays arole in the regulation of cell proliferation.{ECO:0000269|PubMed:11123922, ECO:0000269|PubMed:12047389,ECO:0000269|PubMed:12176985, ECO:0000269|PubMed:12551933,ECO:0000269|PubMed:12882985, ECO:0000269|PubMed:16113678,ECO:0000269|PubMed:17260971, ECO:0000269|PubMed:17407782,ECO:0000269|PubMed:17412999, ECO:0000269|PubMed:17689225,ECO:0000269|PubMed:19137541, ECO:0000269|PubMed:19535339,ECO:0000269|PubMed:19996109, ECO:0000269|PubMed:20068069,ECO:0000269|PubMed:21505792}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | >CLU | chr9:139872144 | chr8:27455767 | ENST00000316403 | - | 7 | 9 | 443_447 | 446 | 450 | Motif | Nuclear localization signal |
| Tgene | >CLU | chr9:139872144 | chr8:27455767 | ENST00000405140 | - | 7 | 9 | 443_447 | 446 | 450 | Motif | Nuclear localization signal |
| Tgene | >CLU | chr9:139872144 | chr8:27455767 | ENST00000523500 | - | 6 | 8 | 443_447 | 446 | 450 | Motif | Nuclear localization signal |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | CLU | chr9:139872144 | chr8:27455767 | ENST00000316403 | - | 7 | 9 | 78_81 | 446 | 450 | Motif | Nuclear localization signal |
| Tgene | CLU | chr9:139872144 | chr8:27455767 | ENST00000405140 | - | 7 | 9 | 78_81 | 446 | 450 | Motif | Nuclear localization signal |
| Tgene | CLU | chr9:139872144 | chr8:27455767 | ENST00000523500 | - | 6 | 8 | 78_81 | 446 | 450 | Motif | Nuclear localization signal |
| Tgene | CLU | chr9:139872144 | chr8:27455767 | ENST00000546343 | - | 7 | 9 | 443_447 | 457 | 461 | Motif | Nuclear localization signal |
| Tgene | CLU | chr9:139872144 | chr8:27455767 | ENST00000546343 | - | 7 | 9 | 78_81 | 457 | 461 | Motif | Nuclear localization signal |
| Tgene | CLU | chr9:139872144 | chr8:27455767 | ENST00000560366 | - | 7 | 9 | 443_447 | 498 | 502 | Motif | Nuclear localization signal |
| Tgene | CLU | chr9:139872144 | chr8:27455767 | ENST00000560366 | - | 7 | 9 | 78_81 | 498 | 502 | Motif | Nuclear localization signal |
Top |
FusionGeneSequence for PTGDS_CLU |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| >In-frame_PTGDS_ENST00000224167_chr9_139872144_+_CLU_ENST00000316403_chr8_27455767_-_41aa >In-frame_PTGDS_ENST00000224167_chr9_139872144_+_CLU_ENST00000405140_chr8_27455767_-_41aa >In-frame_PTGDS_ENST00000371625_chr9_139872144_+_CLU_ENST00000316403_chr8_27455767_-_41aa >In-frame_PTGDS_ENST00000371625_chr9_139872144_+_CLU_ENST00000405140_chr8_27455767_-_41aa |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| >In-frame_PTGDS_ENST00000224167_chr9_139872144_+_CLU_ENST00000316403_chr8_27455767_-_124nt ATGGCTACTCATCACACACTGTGGATGGGACTGGCCCTGCTGGGGGTGCTGGGCGACCTGCAGGCAGCACCGGAGGCCCAGGTCTCCGTG >In-frame_PTGDS_ENST00000224167_chr9_139872144_+_CLU_ENST00000405140_chr8_27455767_-_124nt ATGGCTACTCATCACACACTGTGGATGGGACTGGCCCTGCTGGGGGTGCTGGGCGACCTGCAGGCAGCACCGGAGGCCCAGGTCTCCGTG >In-frame_PTGDS_ENST00000371625_chr9_139872144_+_CLU_ENST00000316403_chr8_27455767_-_124nt ATGGCTACTCATCACACACTGTGGATGGGACTGGCCCTGCTGGGGGTGCTGGGCGACCTGCAGGCAGCACCGGAGGCCCAGGTCTCCGTG >In-frame_PTGDS_ENST00000371625_chr9_139872144_+_CLU_ENST00000405140_chr8_27455767_-_124nt ATGGCTACTCATCACACACTGTGGATGGGACTGGCCCTGCTGGGGGTGCTGGGCGACCTGCAGGCAGCACCGGAGGCCCAGGTCTCCGTG |
| * Fusion transcript sequences (Full-length transcript). |
| >In-frame_PTGDS_ENST00000224167_chr9_139872144_+_CLU_ENST00000316403_chr8_27455767_-_1523nt GCTCCTCCTGCACACCTCCCTCGCTCTCCCACACCACTGGCACCAGGCCCCGGACACCCGCTCTGCTGCAGGAGAATGGCTACTCATCAC ACACTGTGGATGGGACTGGCCCTGCTGGGGGTGCTGGGCGACCTGCAGGCAGCACCGGAGGCCCAGGTCTCCGTGCAGCCCAACTTCCAG CAGGACAAGGGAGGAGTGAGATGTGGATGTTGCTTTTGCACCTACGGGGGCATCTGAGTCCAGCTCCCCCCAAGATGAGCTGCAGCCCCC CAGAGAGAGCTCTGCACGTCACCAAGTAACCAGGCCCCAGCCTCCAGGCCCCCAACTCCGCCCAGCCTCTCCCCGCTCTGGATCCTGCAC TCTAACACTCGACTCTGCTGCTCATGGGAAGAACAGAATTGCTCCTGCATGCAACTAATTCAATAAAACTGTCTTGTGAGCTGATCGCTT GGAGGGTCCTCTTTTTATGTTGAGTTGCTGCTTCCCGGCATGCCTTCATTTTGCTATGGGGGGCAGGCAGGGGGGATGGAAAATAAGTAG AAACAAAAAAGCAGTGGCTAAGATGGTATAGGGACTGTCATACCAGTGAAGAATAAAAGGGTGAAGAATAAAAGGGATATGATGACAAGG TTGATCCACTTCAAGAATTGCTTGCTTTCAGGAAGAGAGATGTGTTTCAACAAGCCAACTAAAATATATTGCTGCAAATGGAAGCTTTTC TGTTCTATTATAAAACTGTCGATGTATTCTGACCAAGGTGCGACAATCTCCTAAAGGAATACACTGAAAGTTAAGGAGAAGAATCAGTAA GTGTAAGGTGTACTTGGTATTATAATGCATAATTGATGTTTTCGTTATGAAAACATTTGGTGCCCAGAAGTCCAAATTATCAGTTTTATT TGTAAGAGCTATTGCTTTTGCAGCGGTTTTATTTGTAAAAGCTGTTGATTTCGAGTTGTAAGAGCTCAGCATCCCAGGGGCATCTTCTTG ACTGTGGCATTTCCTGTCCACCGCCGGTTTATATGATCTTCATACCTTTCCCTGGACCACAGGCGTTTCTCGGCTTTTAGTCTGAACCAT AGCTGGGCTGCAGTACCCTACGCTGCCAGCAGGTGGCCATGACTACCCGTGGTACCAATCTCAGTCTTAAAGCTCAGGCTTTTCGTTCAT TAACATTCTCTGATAGAATTCTGGTCATCAGATGTACTGCAATGGAACAAAACTCATCTGGCTGCATCCCAGGTGTGTAGCAAAGTCCAC ATGTAAATTTATAGCTTAGAATATTCTTAAGTCACTGTCCCTTGTCTCTCTTTGAAGTTATAAACAACAAACTTAAAGCTTAGCTTATGT CCAAGGTAAGTATTTTAGCATGGCTGTCAAGGAAATTCAGAGTAAAGTCAGTGTGATTCACTTAATGATATACATTAATTAGAATTATGG >In-frame_PTGDS_ENST00000224167_chr9_139872144_+_CLU_ENST00000405140_chr8_27455767_-_632nt GCTCCTCCTGCACACCTCCCTCGCTCTCCCACACCACTGGCACCAGGCCCCGGACACCCGCTCTGCTGCAGGAGAATGGCTACTCATCAC ACACTGTGGATGGGACTGGCCCTGCTGGGGGTGCTGGGCGACCTGCAGGCAGCACCGGAGGCCCAGGTCTCCGTGCAGCCCAACTTCCAG CAGGACAAGGGAGGAGTGAGATGTGGATGTTGCTTTTGCACCTACGGGGGCATCTGAGTCCAGCTCCCCCCAAGATGAGCTGCAGCCCCC CAGAGAGAGCTCTGCACGTCACCAAGTAACCAGGCCCCAGCCTCCAGGCCCCCAACTCCGCCCAGCCTCTCCCCGCTCTGGATCCTGCAC TCTAACACTCGACTCTGCTGCTCATGGGAAGAACAGAATTGCTCCTGCATGCAACTAATTCAATAAAACTGTCTTGTGAGCTGATCGCTT GGAGGGTCCTCTTTTTATGTTGAGTTGCTGCTTCCCGGCATGCCTTCATTTTGCTATGGGGGGCAGGCAGGGGGGATGGAAAATAAGTAG AAACAAAAAAGCAGTGGCTAAGATGGTATAGGGACTGTCATACCAGTGAAGAATAAAAGGGTGAAGAATAAAAGGGATATGATGACAAGG >In-frame_PTGDS_ENST00000371625_chr9_139872144_+_CLU_ENST00000316403_chr8_27455767_-_1522nt CTCCTCCTGCACACCTCCCTCGCTCTCCCACACCACTGGCACCAGGCCCCGGACACCCGCTCTGCTGCAGGAGAATGGCTACTCATCACA CACTGTGGATGGGACTGGCCCTGCTGGGGGTGCTGGGCGACCTGCAGGCAGCACCGGAGGCCCAGGTCTCCGTGCAGCCCAACTTCCAGC AGGACAAGGGAGGAGTGAGATGTGGATGTTGCTTTTGCACCTACGGGGGCATCTGAGTCCAGCTCCCCCCAAGATGAGCTGCAGCCCCCC AGAGAGAGCTCTGCACGTCACCAAGTAACCAGGCCCCAGCCTCCAGGCCCCCAACTCCGCCCAGCCTCTCCCCGCTCTGGATCCTGCACT CTAACACTCGACTCTGCTGCTCATGGGAAGAACAGAATTGCTCCTGCATGCAACTAATTCAATAAAACTGTCTTGTGAGCTGATCGCTTG GAGGGTCCTCTTTTTATGTTGAGTTGCTGCTTCCCGGCATGCCTTCATTTTGCTATGGGGGGCAGGCAGGGGGGATGGAAAATAAGTAGA AACAAAAAAGCAGTGGCTAAGATGGTATAGGGACTGTCATACCAGTGAAGAATAAAAGGGTGAAGAATAAAAGGGATATGATGACAAGGT TGATCCACTTCAAGAATTGCTTGCTTTCAGGAAGAGAGATGTGTTTCAACAAGCCAACTAAAATATATTGCTGCAAATGGAAGCTTTTCT GTTCTATTATAAAACTGTCGATGTATTCTGACCAAGGTGCGACAATCTCCTAAAGGAATACACTGAAAGTTAAGGAGAAGAATCAGTAAG TGTAAGGTGTACTTGGTATTATAATGCATAATTGATGTTTTCGTTATGAAAACATTTGGTGCCCAGAAGTCCAAATTATCAGTTTTATTT GTAAGAGCTATTGCTTTTGCAGCGGTTTTATTTGTAAAAGCTGTTGATTTCGAGTTGTAAGAGCTCAGCATCCCAGGGGCATCTTCTTGA CTGTGGCATTTCCTGTCCACCGCCGGTTTATATGATCTTCATACCTTTCCCTGGACCACAGGCGTTTCTCGGCTTTTAGTCTGAACCATA GCTGGGCTGCAGTACCCTACGCTGCCAGCAGGTGGCCATGACTACCCGTGGTACCAATCTCAGTCTTAAAGCTCAGGCTTTTCGTTCATT AACATTCTCTGATAGAATTCTGGTCATCAGATGTACTGCAATGGAACAAAACTCATCTGGCTGCATCCCAGGTGTGTAGCAAAGTCCACA TGTAAATTTATAGCTTAGAATATTCTTAAGTCACTGTCCCTTGTCTCTCTTTGAAGTTATAAACAACAAACTTAAAGCTTAGCTTATGTC CAAGGTAAGTATTTTAGCATGGCTGTCAAGGAAATTCAGAGTAAAGTCAGTGTGATTCACTTAATGATATACATTAATTAGAATTATGGG >In-frame_PTGDS_ENST00000371625_chr9_139872144_+_CLU_ENST00000405140_chr8_27455767_-_631nt CTCCTCCTGCACACCTCCCTCGCTCTCCCACACCACTGGCACCAGGCCCCGGACACCCGCTCTGCTGCAGGAGAATGGCTACTCATCACA CACTGTGGATGGGACTGGCCCTGCTGGGGGTGCTGGGCGACCTGCAGGCAGCACCGGAGGCCCAGGTCTCCGTGCAGCCCAACTTCCAGC AGGACAAGGGAGGAGTGAGATGTGGATGTTGCTTTTGCACCTACGGGGGCATCTGAGTCCAGCTCCCCCCAAGATGAGCTGCAGCCCCCC AGAGAGAGCTCTGCACGTCACCAAGTAACCAGGCCCCAGCCTCCAGGCCCCCAACTCCGCCCAGCCTCTCCCCGCTCTGGATCCTGCACT CTAACACTCGACTCTGCTGCTCATGGGAAGAACAGAATTGCTCCTGCATGCAACTAATTCAATAAAACTGTCTTGTGAGCTGATCGCTTG GAGGGTCCTCTTTTTATGTTGAGTTGCTGCTTCCCGGCATGCCTTCATTTTGCTATGGGGGGCAGGCAGGGGGGATGGAAAATAAGTAGA AACAAAAAAGCAGTGGCTAAGATGGTATAGGGACTGTCATACCAGTGAAGAATAAAAGGGTGAAGAATAAAAGGGATATGATGACAAGGT |
Top |
FusionGenePPI for PTGDS_CLU |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| PTGDS | EGFR, CACNA1A, SHBG, ATXN1, MLH1, PTGDS, CAPN1, BCAT2, RARRES3, ARRB2, PTGDR, HSP90AA1, KRTAP10-7, KRTAP10-3, AKT1, FBXW7, ORM1, CHN2 | CLU | CLU, TGFBR2, MMP25, XRCC6, C8B, C7, C9, LRP2, TGFBR1, SYVN1, H2AFX, COMMD1, NFKB1, NFKBIA, CUL1, BTRC, DISC1, TNIK, GRB2, RAD21, VHL, CHUK, TTR, BAX, CD209, XPO1, ACTN1, ZWINT, KATNA1, KNSTRN, SLC4A1, HBA1, CBY1, ELN, APP, LYZ, ATP7B, ATP7A, BCL2L1, CLUAP1, IL24, HSPD1, PRNP, PON1, FBXO6, PAXIP1, LIG4, MDC1, PDIA3, APOA1, POLR1C, BAG6, CYP2E1, MAPK9, RBBP8, KLF11, RPL23, KEAP1, TSC22D4, FOS, MDM2, CDK19, HSPA1L, NUCB2, TUBB6, TUFM, HSPA5, HSP90B1, HYOU1, UBC, EGFR, RPE, HLA-DPA1, HAX1, CCND3, DPPA4, IL20RB, SUMF2, GPR180, GINM1, SDF4, MMP3, RASSF7, TNF, RNASE13, IFNA5, PLK1, EPPIN, LTF, SEMG1, ADCYAP1R1, SRPK2, CANX, PDGFRA, ARMC6, TUBGCP5, FXR1, SETX, DOCK6, GPAM, ATG3, MAP1LC3A, MCM2, MMP9, VEGFA, SDK2, ATP2B2, PTPRS, TENM3, FAT4, FBXO27, CBWD3, KIAA0355, DHX57, ITGA8, EDEM2, MANEA, DDX31, ARHGAP36, EXTL2, TOR1A, MAN1A1, TNFSF9, PCYOX1L, PTPRF, GNB2, MAN1A2, CELSR1, NLGN2, TXNDC11, INTS5, PCYOX1, MTMR9, OCIAD1, LMAN2L, EIF3F |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for PTGDS_CLU |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Tgene | CLU | P10909 | DB01593 | Zinc | Clusterin | small molecule | approved|investigational |
Top |
RelatedDiseases for PTGDS_CLU |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | PTGDS | C0005586 | Bipolar Disorder | 2 | PSYGENET |
| Hgene | PTGDS | C0036341 | Schizophrenia | 1 | PSYGENET |
| Tgene | CLU | C2609414 | Acute kidney injury | 5 | CTD_human |
| Tgene | CLU | C0002395 | Alzheimer's Disease | 3 | CTD_human |
| Tgene | CLU | C0022658 | Kidney Diseases | 3 | CTD_human |
| Tgene | CLU | C0029408 | Degenerative polyarthritis | 2 | CTD_human |
| Tgene | CLU | C0024141 | Lupus Erythematosus, Systemic | 1 | CTD_human |
| Tgene | CLU | C0025202 | melanoma | 1 | CTD_human |
| Tgene | CLU | C0027686 | Pathologic Neovascularization | 1 | CTD_human |
| Tgene | CLU | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| Tgene | CLU | C0036341 | Schizophrenia | 1 | PSYGENET |
| Tgene | CLU | C0036572 | Seizures | 1 | CTD_human |
| Tgene | CLU | C0041755 | Adverse reaction to drug | 1 | CTD_human |
| Tgene | CLU | C0333641 | Atrophic | 1 | CTD_human |
| Tgene | CLU | C1862939 | AMYOTROPHIC LATERAL SCLEROSIS 1 | 1 | CTD_human |
| Tgene | CLU | C3495559 | Juvenile arthritis | 1 | CTD_human |
| Tgene | CLU | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|